Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -41.96% | -36.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.96% | -36.86% | |||
| Cost of Revenue | -17.12% | 11.29% | |||
| Gross Profit | 13.58% | -24.83% | |||
| SG&A Expenses | -33.17% | -13.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.91% | 0.98% | |||
| Operating Income | 21.26% | -6.50% | |||
| Income Before Tax | 23.49% | -9.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.49% | -9.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.49% | -9.04% | |||
| EBIT | 21.26% | -6.50% | |||
| EBITDA | 21.29% | -6.51% | |||
| EPS Basic | 23.69% | -8.98% | |||
| Normalized Basic EPS | 23.69% | -8.98% | |||
| EPS Diluted | 23.69% | -8.98% | |||
| Normalized Diluted EPS | 23.69% | -8.98% | |||
| Average Basic Shares Outstanding | 0.25% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.25% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||